| Literature DB >> 26053490 |
Pavel Kopel1,2, Dorota Wawrzak3, Vratislav Langer4, Kristyna Cihalova5,6, Dagmar Chudobova7,8, Radek Vesely9, Vojtech Adam10,11, Rene Kizek12,13.
Abstract
1-(1H-Benzimidazol-2-yl)-N-(1H-benzimidazol-2-ylmethyl)methanamine (Entities:
Keywords: benzimidazole; biological activity; coordination compounds; single crystal X-ray diffraction; trimercaptotriazine; trithiocyanuric acid
Mesh:
Substances:
Year: 2015 PMID: 26053490 PMCID: PMC6272323 DOI: 10.3390/molecules200610360
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structural formulas of the ligands used and the complex cation [Ni3(pmdien)3(μ-ttc)](ClO4)3 (3). abb = 1-(1H-benzimidazol-2-yl)-N-(1H-benzimidazol-2-ylmethyl)methanamine, tbb = 2-(1H-benzimidazol-2-ylmethylsulfanyl-methyl)-1H-benzimidazole, ttcH3 = trithiocyanuric acid in its thione and thiol forms.
Figure 2Numbering scheme of 1 with atomic displacement ellipsoids drawn at 30% probability level. Hydrogen atoms are omitted for clarity.
Selected bond lengths (Å) and angles (°) for 1.
| Ni1-N1B | 2.041(3) | Ni2-N5 | 2.030(3) | Ni3-N1F | 2.044(3) |
| Ni1-N1 | 2.047(3) | Ni2-N1C | 2.056(4) | Ni3-N3 | 2.043(3) |
| Ni1-N1A | 2.057(3) | Ni2-N1D | 2.062(4) | Ni3-N1E | 2.057(3) |
| Ni1-O1 | 2.102(3) | Ni2-N22 | 2.101(4) | Ni3-O3 | 2.100(3) |
| Ni1-N11 | 2.121(3) | Ni2-O2 | 2.109(3) | Ni3-N33 | 2.107(3) |
| N1B-Ni1-N1 | 101.50(14) | N5-Ni2-N1C | 99.59(14) | N1F-Ni3-N3 | 100.24(13) |
| N1B-Ni1-N1A | 159.97(15) | N5-Ni2-N1D | 98.94(13) | N1F-Ni3-N1E | 160.83(14) |
| N1-Ni1-N1A | 97.76(13) | N1C-Ni2-N1D | 161.06(14) | N3-Ni3-N1E | 97.92(13) |
| N1B-Ni1-O1 | 92.65(13) | N5-Ni2-N22 | 170.79(14) | N1F-Ni3-O3 | 90.79(14) |
| N1-Ni1-O1 | 97.07(12) | N1C-Ni2-N22 | 80.76(15) | N3-Ni3-O3 | 98.86(13) |
| N1A-Ni1-O1 | 90.41(13) | N1D-Ni2-N22 | 80.33(14) | N1E-Ni3-O3 | 92.42(14) |
| N1B-Ni1-N11 | 80.27(14) | N5-Ni2-O2 | 96.53(12) | N1F-Ni3-N33 | 79.92(14) |
| N1-Ni1-N11 | 165.69(14) | N1C-Ni2-O2 | 90.31(13) | N3-Ni3-N33 | 163.52(14) |
| N1A-Ni1-N11 | 79.71(14) | N1D-Ni2-O2 | 91.45(13) | N1E-Ni3-N33 | 80.92(14) |
| O1-Ni1-N11 | 97.03(13) | N22-Ni2-O2 | 92.67(14) | O3-Ni3-N33 | 97.62(13) |
| N1B-Ni1-S6 | 89.81(10) | N5-Ni2-S4 | 67.54(9) | N1F-Ni3-S2 | 88.42(11) |
| N1-Ni1-S6 | 67.36(9) | N1C-Ni2-S4 | 89.22(10) | N3-Ni3-S2 | 67.60(9) |
| N1A-Ni1-S6 | 92.54(10) | N1D-Ni2-S4 | 94.26(10) | N1E-Ni3-S2 | 92.90(10) |
| O1-Ni1-S6 | 164.40(9) | N22-Ni2-S4 | 103.30(11) | O3-Ni3-S2 | 166.03(10) |
| N11-Ni1-S6 | 98.56(10) | O2-Ni2-S4 | 163.73(9) | N33-Ni3-S2 | 95.98(10) |
Figure 3Projection of the contents of the unit cell along a-axis for 1.
Figure 4Numbering scheme of 2 with atomic displacement ellipsoids drawn at 30% probability level.
Selected bond lengths (Å) and angles (°) for 2.
| S1-C1A | 1.810(4) | S1C-C1C | 1.666(4) | C8A-C3A-N1A | 106.9(3) |
| S1-C1B | 1.828(4) | S2C-C2C | 1.635(4) | N2A-C8A-C3A | 105.9(3) |
| C1A-C2A | 1.490(5) | S3C-C3C | 1.648(4) | C2B-C1B-S1 | 111.4(3) |
| N1A-C2A | 1.332(5) | S1D-C1D | 1.656(4) | C2B-N1B-C3B | 109.4(3) |
| N1A-C3A | 1.405(5) | S2D-C2D | 1.647(4) | C2B-N2B-C8B | 109.8(3) |
| N2A-C2A | 1.335(5) | S3D-C3D | 1.681(4) | N2B-C2B-N1B | 109.0(3) |
| N2A-C8A | 1.389(5) | S1E-C1E | 1.675(4) | N1B-C3B-C8B | 105.9(3) |
| C3A-C8A | 1.404(5) | S2E-C2E | 1.692(4) | N1C-C1C-N3C | 115.0(3) |
| C1B-C2B | 1.485(5) | S3E-C3E | 1.645(4) | N2C-C2C-N1C | 113.5(3) |
| N1B-C2B | 1.331(5) | C1A-S1-C1B | 101.20(18) | N2C-C3C-N3C | 114.1(3) |
| N1B-C3B | 1.397(5) | C2A-C1A-S1 | 115.2(3) | N1D-C2D-N2D | 113.5(3) |
| N2B-C2B | 1.324(5) | C2A-N1A-C3A | 107.7(3) | N2E-C3E-N3E | 113.4(3) |
| N2B-C8B | 1.392(5) | C2A-N2A-C8A | 109.1(3) | ||
| C3B-C8B | 1.397(5) | N1A-C2A-N2A | 110.4(3) |
Figure 5Projection of the contents of the unit cell along a-axis for 2.
Figure 6Testing of antimicrobial activity of 250 μg/mL concentration of ligands and complexes after 24 h of treatment on: (A) S. aureus; (B) E. coli; (C) S. cerevisiae; (D) S. agalactiae; (E) C. striatum; (F) S. marcescens.
Statistical calculation of IC50 by the STATISTICA software version 10.0 from absorbance values after the application of 0; 7.8; 15.6; 31.3; 62.5; 125 and 250 μg/mL concentrations of tested compounds.
| Compounds | IC50 (μg/mL) Measurement after 24 h | |||||
|---|---|---|---|---|---|---|
| Ligand | 5.6 | 19 | 21.4 | 22.4 | 30.8 | 26.7 |
| Ligand | 485.2 | 182.3 | 204.7 | 126.1 | 112.5 | 122.6 |
| Ligand | 625 | 636.8 | 86.4 | 119.5 | 115.8 | 123.9 |
| Complex | 4.8 | 23.7 | 15.4 | 21.4 | 24.3 | 27.2 |
| Complex | 562.3 | 257.6 | 64.3 | 102.1 | 119.5 | 61.5 |
| Complex | 1036.7 | 12.6 | 18.2 | 113.4 | 124.9 | 110.4 |